Alternative transcription initiation leads to expression of a novel ALK isoform in cancer

Nature

Volumn 526, Issue 7573, 2015, Pages 453-457

  Wiesner, Thomas ^a,b   Lee, William ^a   Obenauf, Anna C ^a   Ran, Leili ^a   Murali, Rajmohan ^a   Zhang, Qi Fan ^a   Wong, Elissa W P ^a   Hu, Wenhuo ^a   Scott, Sasinya N ^a   Shah, Ronak H ^a   Landa, Iñigo ^a   Button, Julia ^a,g   Lailler, Nathalie ^a   Sboner, Andrea ^c   Gao, Dong ^a   Murphy, Devan A ^a   Cao, Zhen ^a   Shukla, Shipra ^a   Hollmann, Travis J ^a   Wang, Lu ^a   Borsu, Laetitia ^a   Merghoub, Taha ^a   Schwartz, Gary K ^d   Postow, Michael A ^a,e   Ariyan, Charlotte E ^a   Fagin, James A ^a,e   Zheng, Deyou ^f   Ladanyi, Marc ^a   Busam, Klaus J ^a   Berger, Michael F ^a   Chen, Yu ^a,e   Chi, Ping ^a,e   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; PHOSPHOTRANSFERASE; RNA POLYMERASE II; HISTONE; ISOENZYME; LYSINE; MESSENGER RNA; PROTEIN TYROSINE KINASE;

ALLELE; CANCER; CELLS AND CELL COMPONENTS; CHROMOSOME; ENZYME; GENE EXPRESSION; INHIBITION; MUTATION; RNA; RODENT; TUMOR;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE LOCUS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRON; MELANOMA; MOLECULAR WEIGHT; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; TRANSCRIPTION INITIATION; TRANSCRIPTION INITIATION SITE; 3T3 CELL LINE; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL TRANSFORMATION; CHEMISTRY; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; METABOLISM; METHYLATION; MOLECULAR GENETICS; NEOPLASMS; PROTEIN TERTIARY STRUCTURE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ALLELES; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HISTONES; HUMANS; INTRONS; ISOENZYMES; LYSINE; METHYLATION; MICE; MOLECULAR SEQUENCE DATA; MOLECULAR WEIGHT; NEOPLASMS; NIH 3T3 CELLS; ONCOGENES; PROTEIN STRUCTURE, TERTIARY; RECEPTOR PROTEIN-TYROSINE KINASES; RNA POLYMERASE II; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION, GENETIC;

EID: 84944342787     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature15258     Document Type: Article

References (39)

1. Kouzarides, T. Chromatin modifications and their function. Cell 128, 693-705 (2007).
2. Anders, S., Reyes, A. & Huber, W. Detecting differential usage of exons from RNAseq data. Genome Res. 22, 2008-2017 (2012).
3. GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. Nature Genet. 45, 580-585 (2013).
4. Reis, P. P. et al. mRNA transcript quantification in archival samples using multiplexed, color-coded probes. BMC Biotechnol. 11, 46 (2011).
5. Northcott, P. A. et al. Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. Nature 511, 428-434 (2014).
6. Xie, M. et al. DNA hypomethylation within specific transposable element families associates with tissue-specific enhancer landscape. Nature Genet. 45, 836-841 (2013).
7. Calo, E. & Wysocka, J. Modification of enhancer chromatin: what, how, and why? Mol. Cell 49, 825-837 (2013).
8. Grant, C. E., Bailey, T. L. & Noble, W. S. FIMO: scanning for occurrences of a given motif. Bioinformatics 27, 1017-1018 (2011).
9. Soda, M. et al. Identification of the transforming EML4-ALK fusion gene in nonsmall-cell lung cancer. Nature 448, 561-566 (2007).
10. Lemmon, M. A. & Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 141, 1117-1134 (2010).
11. Bresler, S. C. et al. Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Sci. Transl. Med. 3, 108ra114 (2011).
12. Mossé, Y. P. et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455, 930-935 (2008).
13. Janoueix-Lerosey, I. et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455, 967-970 (2008).
14. Passoni, L. et al. Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. Cancer Res. 69, 7338-7346 (2009).
15. Montavon, G. et al. Wild-type ALK and activating ALK-R1275Q and ALK-F1174L mutations upregulate Myc and initiate tumor formation in murine neural crest progenitor cells. Oncotarget 5, 4452-4466 (2014).
16. Schulte, J. H. et al. High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma. Clin. Cancer Res. 17, 5082-5092 (2011).
17. Cheng, D. T. et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A hybridization capture-based nextgeneration sequencing clinical assay for solid tumor molecular oncology. J. Mol. Diagn. 17, 251-264 (2015).
18. Li, H. et al. The sequence alignment/map format and SAMtools. Bioinformatics 25, 2078-2079 (2009).
19. Trapnell, C., Pachter, L. & Salzberg, S. L. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25, 1105-1111 (2009).
20. McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297-1303 (2010).
21. Robinson, J. T. et al. Integrative genomics viewer. Nature Biotechnol. 29, 24-26 (2011).
22. Carbon, S. et al. AmiGO: online access to ontology and annotation data. Bioinformatics 25, 288-289 (2009).
23. Mathelier, A. et al. JASPAR 2014: an extensively expanded and updated openaccess database of transcription factor binding profiles. Nucleic Acids Res. 42, D142-D147 (2014).
24. Chi, P. et al. ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature 467, 849-853 (2010).
25. Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9, R137 (2008).
26. Won,H.H., Scott, S. N., Brannon, A. R., Shah, R. H.& Berger, M. F. Detecting somatic genetic alterations in tumor specimens by exon capture and massively parallel sequencing. J. Vis. Exp. e50710 (2013).
27. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760 (2009).
28. DePristo, M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nature Genet. 43, 491-498 (2011).
29. Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nature Biotechnol. 31, 213-219 (2013).
30. Rausch, T. et al. DELLY: structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics 28, i333-i339 (2012).
31. Krueger, F. & Andrews, S. R. Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications. Bioinformatics 27, 1571-1572 (2011).
32. Boeva, V. et al. Control-free calling of copy number alterations in deep-sequencing data using GC-content normalization. Bioinformatics 27, 268-269 (2011).
33. Wang, J. et al. CREST maps somatic structural variation in cancer genomes with base-pair resolution. Nature Methods 8, 652-654 (2011).
34. McLaren, W. et al. Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. Bioinformatics 26, 2069-2070 (2010).
35. Krzywinski, M. et al. Circos: an information aesthetic for comparative genomics. Genome Res. 19, 1639-1645 (2009).
36. Geiss, G. K. et al. Direct multiplexed measurement of gene expression with colorcoded probe pairs. Nature Biotechnol. 26, 317-325 (2008).
37. Bennett, D. C., Cooper, P. J. & Hart, I. R. A line of non-tumorigenic mouse melanocytes, syngeneic with the B16 melanoma and requiring a tumour promoter for growth. Int. J. Cancer 39, 414-418 (1987).
38. Refaeli, Y., Van Parijs, L., Alexander, S. I.&Abbas, A. K. Interferongamma is required for activation-induced death of T lymphocytes. J. Exp. Med. 196, 999-1005 (2002).
39. Ponomarev, V. et al. A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging. Eur. J. Nucl. Med. Mol. Imaging 31, 740-751 (2004).